(redirected from Cardene sr)
Also found in: Medical.
Related to Cardene sr: nicardipine


A calcium channel blocker drug, C26H29N3O6, that acts as a coronary vasodilator and is used in its hydrochloride form to treat hypertension.

[ni(tro)- + car(boxyl) + di(hydro)p(yr)idine, class of drugs to which it belongs.]
References in periodicals archive ?
3 million in sales of Cardene SR, the rights to which the company acquired from Roche in September 2006.
5 mg BID or DyanaCirc CR 5 mg QD (SR) Nicardipine (*) Cardene, 20 mg TID or Cardene SR 30 mg BID (SR) Nifedipine Adalat CC, 30 mg QD Procardia XL Nisoldipine Sular 20 mg QD Verapamil (*) Calan, 80 mg TID or Calan SR, 120-240 mg QD Isoptin, (SR) Isoptin SR, Verelan, Verelan PM Classification/Drug Usual Dosage Range Amlodipine 2.
0 million of Cardene SR to wholesale customers in the United States.
A new sustained release formulation of Cardene(R) (nicardipine hydrochloride) -- Cardene SR -- was recently approved for marketing by the United States Food and Drug Administration (FDA).
The five, all of which were approved for marketing in the last three-and- a-half years, are: Toradol IM (injectable) and Toradol Oral, effective non-opoid, non-steroidal anti-inflammatory pain-relievers prescribed for the limited-duration management of pain; Ticlid, an anti-platelet aggregator prescribed for stroke risk reduction in women who are at risk of a first or recurrent stroke, men at risk of a recurrent stroke and male TIA patients who cannot take aspirin; Synarel, a gonadotropin-releasing hormone agonist prescribed for the management of endometriosis and to treat central precocious puberty; Cytovene; and Cardene and Cardene SR, calcium-channel blockers marketed for the treatment of hypertension (high blood pressure).
Cardene SR capsules, the sustained-release formulation of the calcium-channel blocker Cardene, will be prescribed by physicians for twice-daily use for the treatment of hypertension (high blood pressure).
plus Cardene SR net product sales for the 12 months ended September 30, 2007 were $143.
Upon conclusion of final labeling discussions with the FDA, Syntex expects to be granted final approval to market Cardene SR.